Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SBT6050 |
Synonyms | |
Therapy Description |
SBT6050 comprises a TLR8 (CD288) agonist linked to an Erbb2 (Her2) monoclonal antibody, which may lead to activation of TLR8 expressing myeloid cells in the context of Erbb2 (Her2)-expressing tumors, potentially resulting in increased anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 4537). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SBT6050 | SBT-6050|SBT 6050|ImmunoTAC SBT6050|HER2-directed TLR8 Agonist SBT6050 | HER2 (ERBB2) Antibody 76 TLR8 Agonist 9 | SBT6050 comprises a TLR8 (CD288) agonist linked to an Erbb2 (Her2) monoclonal antibody, which may lead to activation of TLR8 expressing myeloid cells in the context of Erbb2 (Her2)-expressing tumors, potentially resulting in increased anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 4537). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04460456 | Phase I | SBT6050 Pembrolizumab + SBT6050 Cemiplimab + SBT6050 | A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | Unknown status | USA | AUS | 1 |